Published in Br J Clin Pharmacol on October 30, 2006
Monitoring drug therapy. Br J Clin Pharmacol (2012) 1.02
Appropriateness of serum digoxin levels. Eur J Clin Pharmacol (2007) 0.87
Appropriateness of digoxin measurement in hospitalized patients. Biochem Med (Zagreb) (2017) 0.75
Digoxin in the management of cardiovascular disorders. Circulation (2004) 1.76
Digoxin therapeutic drug monitoring: an audit and review. N Z Med J (2003) 1.63
A computer-based intervention for improving the appropriateness of antiepileptic drug level monitoring. Am J Clin Pathol (2003) 1.33
Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem Fund Q Health Soc (1984) 1.23
Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med (1974) 1.04
An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit (1983) 1.03
Use and misuse of a digoxin assay service. Br Med J (Clin Res Ed) (1986) 0.99
Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol (2001) 0.96
Strategies for physician education in therapeutic drug monitoring. Clin Chem (1998) 0.96
Abbott AxSYM random and continuous access immunoassay system for improved workflow in the clinical laboratory. Clin Chem (1993) 0.84
Evaluation of a digoxin pharmacokinetic monitoring service in a community hospital. Drug Intell Clin Pharm (1985) 0.82
Effect of data collection method on results of serum digoxin concentration audit. Am J Hosp Pharm (1988) 0.80
Audit exposes flawed blood sampling for "digoxin levels". Ther Drug Monit (1992) 0.80
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics (2005) 2.98
Associations between the anticholinergic risk scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc (2011) 1.56
Off-label prescribing in older patients. Drugs Aging (2012) 1.55
Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging (2012) 1.52
Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos (2004) 1.51
Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence? Age Ageing (2013) 1.41
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos (2005) 1.41
Adjusting for brachial artery diameter in the analysis of flow-mediated dilatation: pitfalls of a landmark paper? Atherosclerosis (2013) 1.40
Plasma erythromycin concentrations predict feeding outcomes in critically ill patients with feed intolerance. Crit Care Med (2011) 1.39
The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol (2013) 1.39
Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos (2003) 1.30
In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos (2006) 1.20
Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol (2006) 1.12
Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics (2007) 1.07
Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. J Hypertens (2012) 1.06
Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther (2007) 1.06
The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos (2008) 1.05
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol (2009) 1.02
Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J Biol Chem (2008) 1.02
Drug burden index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol (2011) 1.01
S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol (2005) 1.01
An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol (2006) 1.00
Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol (2008) 0.98
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol (2014) 0.97
The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos (2008) 0.95
Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol (2006) 0.95
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol (2010) 0.95
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol (2006) 0.94
Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol (2004) 0.93
The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol (2011) 0.92
Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol (2006) 0.91
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol (2011) 0.91
Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. J Chem Inf Comput Sci (2003) 0.90
In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther (2010) 0.90
In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol (2007) 0.89
Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther (2004) 0.89
The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. Mol Pharmacol (2010) 0.89
In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol (2002) 0.89
Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol (2004) 0.88
Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat. J Neurosci Methods (2002) 0.88
Anticholinergic drugs and functional outcomes in older patients undergoing orthopaedic rehabilitation. Am J Geriatr Pharmacother (2012) 0.88
Association between prescribing of antimuscarinic drugs and antimuscarinic adverse effects in older people. Expert Rev Clin Pharmacol (2010) 0.87
Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease. Expert Opin Drug Metab Toxicol (2009) 0.87
The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos (2008) 0.87
The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. Drug Metab Dispos (2013) 0.87
Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates. J Med Chem (2008) 0.86
Clinical and demographic factors associated with antimuscarinic medication use in older hospitalized patients. Hosp Pract (1995) (2011) 0.86
The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. Pharmacol Ther (2012) 0.85
Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther (2007) 0.85
Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibitors for heart failure. Eur J Heart Fail (2003) 0.85
Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. J Pharmacol Exp Ther (2014) 0.85
Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics (2002) 0.85
Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry (2004) 0.84
Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol (2013) 0.84
Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board. Geriatr Gerontol Int (2013) 0.84
Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. Expert Opin Drug Metab Toxicol (2007) 0.84
Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates. Curr Drug Metab (2008) 0.84
Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev (2010) 0.84
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance. Drug Metab Dispos (2012) 0.84
Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol (2007) 0.83
Acute hypotensive effects of oral cisapride and erythromycin in healthy subjects. Br J Clin Pharmacol (2004) 0.83
Effects of pre- vs. intra-dialysis folic acid on arterial wave reflections and endothelial function in patients with end-stage renal disease. Br J Clin Pharmacol (2008) 0.83
Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochem Pharmacol (2012) 0.83
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol (2009) 0.83
Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos (2009) 0.83
Effects of folic acid supplementation on psychomotor performance and hemorheology in healthy elderly subjects. Arch Gerontol Geriatr (2005) 0.82
In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochem Pharmacol (2008) 0.82
Characterisation of the binding of cationic amphiphilic drugs to phospholipid bilayers using surface plasmon resonance. ChemMedChem (2007) 0.82
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics (2006) 0.82
Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. Chem Res Toxicol (2007) 0.82
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem (2003) 0.82
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol (2007) 0.81
Assessing the adverse effects of antimuscarinic drugs in older patients: which way forward? Expert Rev Clin Pharmacol (2011) 0.81
Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos (2009) 0.81
Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity. Expert Opin Drug Metab Toxicol (2005) 0.81
The importance of local chemical structure for chemical metabolism by human uridine 5'-diphosphate-glucuronosyltransferase. J Chem Inf Model (2006) 0.81
Inhibition of morphine metabolism by ketamine. Drug Metab Dispos (2010) 0.81
Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol (2007) 0.81
AFM study of the interaction of cytochrome P450 2C9 with phospholipid bilayers. Chem Phys Lipids (2009) 0.80
High-resolution transthoracic echocardiography of the left anterior descending coronary artery: a novel noninvasive assessment of coronary vasoreactivity. J Am Soc Echocardiogr (2007) 0.80
Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model (2006) 0.80
The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin Drug Metab Toxicol (2007) 0.80
Predicting and detecting adverse drug reactions in old age: challenges and opportunities. Expert Opin Drug Metab Toxicol (2012) 0.80
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling. Pharmacogenet Genomics (2016) 0.80
In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol (2011) 0.79
Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J Med Chem (2004) 0.79
Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. Drug Metab Dispos (2011) 0.79
Asymmetric dimethylarginine: a possible link between vascular disease and dementia. Curr Alzheimer Res (2013) 0.79
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol (2014) 0.79
"Phase I and Phase II" drug metabolism: terminology that we should phase out? Drug Metab Rev (2005) 0.79
Analysis of short-term reproducibility of arterial vasoreactivity by pulse-wave analysis after pharmacological challenge. Clin Exp Pharmacol Physiol (2008) 0.79
Influence of comorbidities and medication use on tilt table test outcome in elderly patients. Pacing Clin Electrophysiol (2007) 0.79
Kinetics membrane disruption due to drug interactions of chlorpromazine hydrochloride. Langmuir (2009) 0.79
Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem Pharmacol (2007) 0.79
Lateral heterogeneities in supported bilayers from pure and mixed phosphatidylethanolamine demonstrating hydrogen bonding capacity. Biointerphases (2008) 0.79